Abstract
A new series of compounds 2-((1-(4-(4-arylidene-2-methyl-5-oxo-4,5-dihydro-1H-imidazol-1-yl)phenyl)ethylidene)hydrazono)thiazolidin-4-ones (4a–o) have been synthesized under conventional and microwave irradiation method. All compounds were characterized by IR, 1H NMR, 13C NMR and mass spectra. Newly synthesized compounds were screened for their antibacterial and antifungal activities on Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus pyogenes, Candida albicans, Aspergillus niger and Aspergillus clavatus by bioassays, namely serial broth dilution. The synthesized compounds showed potent antimicrobial activity against tested microorganisms. Compounds 4h, 4j, 4m and 4n were the most potent amongst tested compounds.
Similar content being viewed by others
References
Abdel-Meguid SS, Metcalf BW, Carr TJ, Demarsh P, DesJarlais RL, Fisher S, Green DW, Ivanoff L, Lambert DM (1994) An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: crystallographic and pharmacokinetic analysis. Biochemistry 33:11671–11677. doi:10.1021/bi00205a001
Clarke RW, Harris J (2002) RX 821002 as a tool for physiological investigation of α 2-adrenoceptors. CNS Drug Rev 8:177–192. doi:10.1111/j.1527-3458.2002.tb00222.x
Dandia A, Singh R, Bhaskaran S, Samant SD (2011) Versatile three component procedure for combinatorial synthesis of biologically relevant scaffold spiro[indole-thiazolidinones] under aqueous conditions. Green Chem 13:1852–1859. doi:10.1039/C0GC00863J
Desai NC, Maheta AS, Rajpara KM, Joshi VV, Vaghani HV, Satodiya HM (2011) Green synthesis of novel quinoline based imidazole derivatives and evaluation of their antimicrobial activity. J Saudi Chem Soc (in press). doi:10.1016/j.jscs.2011.11.021
Desai NC, Rajpara KM, Joshi VV, Vaghani HV, Satodiya HM (2012a) Synthesis and characterization of some new thiazole based thiazolidinone derivatives as potent antimicrobial and antimycobacterial agents. Anti-Infective Agents 10:75–86
Desai NC, Pandya DD, Joshi VV, Rajpara KM, Vaghani HV, Satodiya HM (2012b) Synthesis, characterization and antimicrobial screening of hybrid molecules containing benzimidazole-pyrazole and pyridine nucleus. Med Chem Res. doi:10.1007/s00044-012-9990-4
Desai NC, Pandya MR, Rajpara KM, Joshi VV, Vaghani HV, Satodiya HM (2012c) Synthesis and antimicrobial screening of novel series of imidazo-[1,2-a]pyridine derivatives. Med Chem Res. doi:10.1007/s00044-012-9988-y
Desai NC, Rajpara KM, Joshi VV, Vaghani HV, Satodiya HM (2012d) Synthesis of promising antimicrobial agents—a novel series of N-(4-(2,6-dichloroquinolin-3-yl)-6-(aryl)pyrimidin-2-yl)-2-morpholinoacetamides. Med Chem Res. doi:10.1007/s00044-012-0121-z
Desai NC, Joshi VV, Rajpara KM, Vaghani HV, Satodiya HM (2012e) Facile synthesis of novel fluorine containing pyrazole based thiazole derivatives and evaluation of antimicrobial activity. J Fluor Chem. doi: 10.1016/j.jfluchem.2012.06.021
Diurno MV, Mazzoni O, Capasso F, Izzo AA, Bolognese A (1997) Synthesis and pharmacological activity of 2-(substituted phenyl)-3-[2 or 3-[(4-substituted phenyl-4-hydroxy)piperidino]ethyl or propyl]-1,3-thiazolidin-4-ones. Farmaco 52:237–241
Finegold SM, Garrod L (1995) Bailey and Scott’s diagnostic microbiology, 8th edn., chap 13. C.V. Mosby, Toronto, pp 171–193
Gangneux JP, Dullin M, Sulahian A, Garin YJF, Derouin F (1999) Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum. Antimicrob Agents Chemother 43:172–174
Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW (1997) Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46:433–439
Havrylyuk D, Zimenkovsky B, Lesyk R (2009) Synthesis and anticancer activity of novel nonfused bicyclic thiazolidinone derivatives. Phosphorus, Sulfur Silicon Relat Elem 184:638–650. doi:10.1080/10426500802247563
Kato T, Ozaki T, Ohi N (1999a) Improved synthetic methods of CP-060S, a novel cardioprotective drug. Tetrahedron Asymmetry 10:3963–3968. doi:10.1016/S0957-4166(99)00441-3
Kato Y, Kita Y, Nishio M, Hirasawa Y, Ito K, Yamanaka T, Motoyama Y, Seki J (1999b) In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur J Pharmacol 384:197–202. doi:10.1016/S0014-2999(99)00658-5
Knutsen LJS, Hobbs CJ, Earnshaw CG, Fiumana A, Gilbert J, Mellor SL, Radford F, Smith NJ, Birch PJ, Burley JR, Ward SDC, James IF (2007) Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett 17:662–667. doi:10.1016/j.bmcl.2006.10.098
Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA (2002) Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 62:58–64
Laufer SA, Zimmermann W, Ruff KJ (2004) Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position. J Med Chem 47:6311–6325. doi:10.1021/jm0496584
Lisnock JM, Griffin P, Calaycay J, Frantz B, Parsons J, O’Keefe SJ, LoGrasso P (2002) Activation of JNK3α1 requires both MKK4 and MKK7: kinetic characterization of in vitro phosphorylated JNK3α1. Biochemistry 39:3141–3148. doi:10.1021/bi992410+
Muller G (2003) Medicinal chemistry of target family-directed masterkeys. Drug Discov Today 8:681–691. doi:10.1016/S1359-6446(03)02781-8
Nair MD, Nagarajan K (1983) Nitroimidazoles as chemotherapeutic agents. Prog Drug Res 27:163–252
Norisada N, Masuzaki H, Fujimoto M, Inoue G, Hosoda K, Hayashi T, Watanabe M, Muraoka S, Yoneda F, Nakao K (2004) Antidiabetic and adipogenic properties in a newly synthesized thiazolidine derivative, FPFS-410. Metabolism 53:1532–1537. doi:10.1016/j.metabol.2004.06.020
Ottana R, Mazzon E, Dugo L, Monforte F, Maccari R, Sautebin L, Luca GDe, Vigorita MG, Alcaro S, Ortuso F (2002) Modeling and biological evaluation of 3,3′-(1,2-ethanediyl)bis[2-(4-methoxyphenyl)-thiazolidin-4-one], a new synthetic cyclooxygenase-2 inhibitor. Eur J Pharmacol 448:71–80. doi:10.1016/S0014-2999(02)01888-5
Previtera T, Vigorita MG, Basile M, Orsini F, Benetollo F, Bombieri G (1994) 3,3′-Di [1,3-thiazolidine-4-one] system. VI. Structural and conformational studies on configurational isomers with antihistaminic activity. Eur J Med Chem 29:317–324. doi:10.1016/0223-5234(94)90102-3
Ragab FA, Eid NM, el-Tawab HA (1997) Synthesis and anticonvulsant activity of new thiazolidinone and thioxoimidazolidinone derivatives derived from furochromones. Pharmazie 52:926–929
Raghubir R, Verma R, Samuel SS, Raza S, Haq W, Katti SB (2011) Anti-stroke profile of thiazolidin-4-one derivatives in focal cerebral ischemia model in rat. Chem Biol Drug Design 78:445–453. doi:10.1111/j.1747-0285.2011.01153.x
Ravichandran V, Jain A, Kumar KS, Rajak H, Agrawal RK (2011) Design, synthesis, and evaluation of thiazolidinone derivatives as antimicrobial and anti-viral agents. Chem Biol Drug Design 78:464–470. doi:10.1111/j.1747-0285.2011.01149.x
Rawal RK, Prabhakar YS, Katti SB, DeClercq E (2005) 2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT Inhibitors. Bioorg Med Chem 13:6771–6776. doi:10.1016/j.bmc.2005.07.063
Riddell D, Bright CP, Burton BJ, Bush RC, Harris NV, Hele D, Moore UM, Naik K, Parrott DP, Smith C, Williams RJ (1996) Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol. Biochem Pharmacol 52:1177. doi:10.1016/0006-2952(96)00455-8
Sakashita H, Akahoshi F, Kitajima H, Hayashi Y, Tsutsumiuchi R (2006) [(S)-γ-(Arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors. Bioorg Med Chem 14:3662–3671. doi:10.1016/j.bmc.2006.01.022
Takle AK, Brown MJ, Davies S, Dean DK, Francis G, Gaiba A, Hird AW, King FD, Lovell PJ, Naylor A, Reith AD, Steadman JG, Wilson DM (2006) The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett 16:378–381. doi:10.1016/j.bmcl.2005.09.072
Tanabe Y, Suzukamo G, Komuro Y, Imanishi N, Morooka S, Enomoto M, Kojima A, Sanemitsu Y, Mizutani M (1991) Structure-activity relationship of optically active 2-(3-pyridyl)thiazolidin-4-ones as a PAF antagonists. Tetrahedron Lett 32:379–382. doi:10.1016/S0040-4039(00)92633-9
Ulrich S, Roland U, Albrecht L, Helmut G, Bernd P, Johanna B, Karin W, Peter F (1987) Amino acids and peptides; 59.1 synthesis of biologically active cyclopeptides; 9.2 synthesis of 16 isomers of dolastatin 3; 3 I. Synthesis of the 2-(1-aminoalkyl)-thiazole-4-carboxylic acids. Synthesis 3:233–236
Voss ME, Carter PH, Tebben AJ, Scherle PA, Brown GD, Thampson LA, Xu M, Lo YC, Liu RQ, Strzemienski P, Everlof JG, Trzaskos JM, Decicco CP (2003) Both 5-arylidene-2-thioxodihydropyrimidine-4,6(1H,5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones are light-dependent tumor necrosis factor-α antagonists. Bioorg Med Chem Lett 13:533–538. doi:10.1016/S0960-894X(02)00941-1
Acknowledgments
We would like to express our sincere gratitude to the Department of Chemistry, Mahatma Gandhi Campus, Maharaja Krishnakumarsinhji Bhavnagar University, Bhavnagar for providing research and library facilities.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Desai, N.C., Joshi, V.V., Rajpara, K.M. et al. Microwave-assisted synthesis and antimicrobial screening of new imidazole derivatives bearing 4-thiazolidinone nucleus. Med Chem Res 22, 1893–1908 (2013). https://doi.org/10.1007/s00044-012-0190-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-012-0190-z